Moberg Pharma AB (CHIX:MOBs)
kr 33.14 0 (0%) Market Cap: 1.71 Bil Enterprise Value: 1.68 Bil PE Ratio: 0 PB Ratio: 1.74 GF Score: 36/100

Q1 2021 Moberg Pharma AB (publ) Earnings Call Transcript

May 11, 2021 / 01:00PM GMT
Release Date Price: kr72.3
Operator

Hello, and welcome to the Moberg Pharma Q1 report. (Operator Instructions) Just to remind you, this conference call is being recorded. Today, I'm pleased to present CEO, Anna Ljung. Please go ahead with your meeting.

Anna Ljung;publ;CEO
Moberg Pharma AB

()-

Thank you. Hi. My name is Anna Ljung, and I'm the CEO of Moberg Pharma. I also have our VP of Finance, Mark Beveridge, on the call today. We're happy to present the Q1 report, and you will find the report on our website. And there, you also have a PowerPoint presentation, and that's the presentation that I will be basing this telephone meeting on.

So I'll start on Page 3 in that presentation with an overall. So we're a Swedish pharmaceuticals company that bases our products on drug delivery of known substances, which reduces time to market and development risk compared to traditional drug development. And our lead program is MOB-015 in onychomycosis, nail fungus, and there we see a global sales potential of $250 million to $500 million annually. We recently finalized

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot